Earth Science Tech (ETST) Income from Non-Controlling Interests (2025 - 2026)
Earth Science Tech (ETST) posted Income from Non-Controlling Interests of -$580.0 for Q1 2026, down 6344.44% on a QoQ basis from -$9.0 in Q4 2025.
Earth Science Tech (ETST) Income from Non-Controlling Interests (2025 - 2026) Analysis & Trends
Earth Science Tech's Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at -$580.0 for Q1 2026.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$580.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29840.0 (changed N/A YoY) and the FY2026 annual result came in at -$29839.0, changed N/A from the prior year.
- Income from Non-Controlling Interests was -$580.0 for Q1 2026 at Earth Science Tech, down from -$9.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$9.0 in Q4 2025 and bottomed at -$20926.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.68 Bn | 30.74 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.34 Bn | 18.54 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | - |
| 10 | Earth Science Tech | 35.17 Mn | 33.01 Mn | 6.27 Mn | -580.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -580.00 |
| Dec 31, 2025 | -9.00 |
| Sep 30, 2025 | -20,926.00 |
| Jun 30, 2025 | -8,325.00 |